@article{eed9952d78b44eb6b21bee88d201db94,
title = "2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting",
abstract = "• Nausea and vomiting are considered amongst the most troublesome adverse events for patients receiving antineoplastics. • The guideline covers emetic risk classification, prevention and management of treatment-induced nausea and vomiting. • The Consensus Committee consisted of 34 multidisciplinary, health care professionals and three patient advocates. • Recommendations are based on evidence-based data (level of evidence) and the authors{\textquoteright} collective expert opinion (grade). • All recommendations are for the first course of antineoplastic therapy; modifications may be needed in subsequent courses.",
keywords = "Humans, Vomiting/prevention & control, Nausea/prevention & control, Radiation Oncology",
author = "{participants of the MASCC/ESMO Consensus Conference 2022} and J Herrstedt and R Clark-Snow and Ruhlmann, {C H} and A Molassiotis and I Olver and Rapoport, {B L} and M Aapro and K Dennis and Hesketh, {P J} and Navari, {R M} and L Schwartzberg and Affronti, {M L} and Garcia-Del-Barrio, {M A} and A Chan and L Celio and R Chow and M Fleury and Gralla, {R J} and R Giusti and F Jahn and H Iihara and E Maranzano and V Radhakrishnan and M Saito and P Sayegh and S Bosnjak and L Zhang and J Lee and V Ostwal and T Smit and A Zilic and K Jordan and F Scott{\'e}",
year = "2024",
month = feb,
doi = "10.1016/j.esmoop.2023.102195",
language = "English",
volume = "9",
journal = "ESMO Open",
issn = "2059-7029",
publisher = "BMJ Publishing Group",
number = "2",
}